<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00422721</url>
  </required_header>
  <id_info>
    <org_study_id>BRD 06/8-F</org_study_id>
    <secondary_id>ID RCB 2006-A00192-49</secondary_id>
    <nct_id>NCT00422721</nct_id>
  </id_info>
  <brief_title>Genetic Study of Patients Suffering From Congenital Amaurosis of Leber or From an Early Severe Retinal Dystrophy</brief_title>
  <official_title>Genetical, Multi-center, Prospective Study of Phenotyping and Genotyping of Patients Suffering From Congenital Amaurosis of Leber or From an Early Severe Retinal Dystrophy in the Aim of the Realisation of a Clinical Trial of Gene Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retinal dystrophies are responsible for numerous cases of blindness, and there are no
      therapeutic possibilities today. Gene therapy is efficient in a dog model concerning
      dystrophy linked to a mutation of the rpe65 gene. If such a therapy is to be considered for
      humans, it is urgent to select, at a national level, patients suffering from dystrophy linked
      to a mutation of the rpe65 gene. The systematic correlation of phenotype/genotype is an
      anatomical-functional approach, but it also identifies patients who may be potentially
      included in a future gene therapy study. Indeed, identification of people with a mutation of
      rpe65 is still insufficient in France (compared to other European countries) because of a
      lack of systemic genotyping of retinal dystrophy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Amaurosis</condition>
  <condition>Retinal Diseases</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>realization of a family tree</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>refractometry</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>evaluation of the presence of a nystagmus</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ocular behavior</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>test of baby vision</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>test of keenness</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>reading test</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>visual field</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>color vision</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>electroretinographical activity</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biomicroscopical test</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>retinal imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>retinal autofluorescence</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>genotyping</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with clinical characteristics of amaurosis of Leber

          -  Patients suffering from an early severe retinal dystrophy

          -  Patients with social insurance

          -  Patients with a consent form signed

        Exclusion Criteria:

          -  Retinal dystrophy with autosomal dominant transmission

          -  Retinal dystrophy occuring after 5 years of age

          -  Syndromical retinal dystrophy with one or more systemic manifestations

          -  Familial macular degeneration

          -  Familial choroid dystrophy

          -  Non-degenerative retinopathology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Weber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nantes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sabine Defoort, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernard Puech, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabelle Drumaré, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Hamel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Montpellier</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carl Arndt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Montpellier</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier Roche, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Necker</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christophe Orssaud, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Necker</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emmanuel Bui Quoc, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Necker</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Saddek Mohand Saïd, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CNO XV-XX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José-Alain Sael, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CNO XV-XX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hélène Dollfus-Waltmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Strasbourg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2007</study_first_submitted>
  <study_first_submitted_qc>January 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2007</study_first_posted>
  <last_update_submitted>November 23, 2011</last_update_submitted>
  <last_update_submitted_qc>November 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2011</last_update_posted>
  <keyword>early severe retinal dystrophy</keyword>
  <keyword>amaurosis of leber</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Blindness</mesh_term>
    <mesh_term>Retinal Dystrophies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

